Open versus robotic-assisted radical cystectomies: A risk analysis.

Authors

null

Rishabh Simhal

Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

Rishabh Simhal , Kerith Ruoyao Wang , Yash Shah , Daniel P Simon , James Ryan Mark , Mihir S Shah , Leonard G. Gomella , Thenappan Chandrasekar , Costas D. Lallas

Organizations

Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, Department of Urology, University of California Davis, Sacramento, CA

Research Funding

No funding received
None.

Background: Radical cystectomy (RC) is standard of care for muscle-invasive bladder cancer, but it comes with significant perioperative risk with half of patients experiencing major postoperative complications. Robot-assisted radical cystectomies (RARC) have aimed to decrease patient morbidity and have become increasingly adopted in North America. Currently, both open radical cystectomies (ORC) and RARC are frequently performed. To contribute to the existing literature using newly available data from the American College of Surgeons National Surgical Quality Improvement Project (NSQIP), representing one of the most recent, largest multi-institutional studies, while uniquely accounting for a variety of factors including type of urinary diversion, cancer staging, and neoadjuvant chemotherapy. Methods: RC procedures performed between 2019-2020 were identified in NSQIP and the corresponding Cystectomy Targeted database. Cases in the ORC group were planned open procedures, and cases in the RARC group were robotic with intra- or extracorporeal diversions, including unplanned conversion to open cases for intention-to-treat. Chi-square and t-tests were performed to compare baseline demographics and operative parameters. Multivariate analysis was performed for outcomes including major complications, minor complications, and 30-day mortality, while adjusting for operative approach, medical comorbidities, functional status, age, race, sex, BMI, ASA-classification, preoperative labs, type of urinary diversion, pathological staging, prior pelvic surgery or radiation, need for preoperative transfusion, preoperative sepsis, emergent or elective surgery, and recent chemotherapy. Results: 4,022 RC cases were identified. Of these, 3,146 (78.2%) received planned ORC while 876 (21.8%) received RARC. Baseline demographics of the patients who received ORC versus RARC were largely similar, with no significant difference in age or medical comorbidities. RARC was associated with longer operative times and shorter hospital length of stay compared to ORC. On multivariate analysis, ORC was associated with a higher rate of 30-day mortality [OR 3.1; 95% CI 1.3-7.2; p=0.009], reintubation, cardiac arrest, superficial wound infection, bleeding requiring transfusion [OR 4.7; 95%CI 3.6 - 6.1; p<0.001], prolonged postoperative nasogastric tube use, rectal injury, and ureteral fistula or urine leak compared to RARC. Conclusions: In the NSQIP database, ORC is associated with higher rates of 30- day mortality and operative complications, most notably bleeding, compared to RARC. This study is unique in the size of the cohorts compared, the timeliness of the data (2019-2020), and the ability to control for factors, such as type of urinary diversion, pathological bladder cancer staging, and use of neoadjuvant chemotherapy.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4593)

DOI

10.1200/JCO.2023.41.16_suppl.4593

Abstract #

4593

Poster Bd #

85

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

The impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes.

First Author: Kerith Ruoyao Wang

Abstract

2023 ASCO Genitourinary Cancers Symposium

Risk analysis of open vs. robotic assisted radical cystectomy.

First Author: Rishabh Kumar Simhal

Abstract

2023 ASCO Genitourinary Cancers Symposium

Impact of neoadjuvant chemotherapy on 30-day radical cystectomy outcomes.

First Author: Rishabh Kumar Simhal